Question 1

What are Khavinson bioregulator peptides and how are they different from other peptides?

Accepted Answer

Khavinson bioregulator peptides are a class of ultra-short synthetic peptides (2–4 amino acids) developed by Professor Vladimir Khavinson in Russia over several decades. Unlike typical therapeutic peptides that bind cell-surface receptors, bioregulators are theorized to penetrate cells, enter the nucleus, and bind specific DNA sequences to regulate gene expression in a tissue-specific manner. Each bioregulator targets a specific organ: Pinealon for the pineal gland, Cortagen for the cerebral cortex, Epithalon for the pineal/telomerase system, Thymalin for the thymus, etc. This approach is widely used in Russian medicine but has limited acceptance in Western science due to the unconventional mechanism of action and the majority of research being published in Russian-language journals.

Question 2

How does Pinealon compare to melatonin supplements?

Accepted Answer

Pinealon and melatonin work at fundamentally different levels. Melatonin supplements directly provide the hormone — essentially hormone replacement. Pinealon, if the bioregulator model is accurate, works upstream by normalizing the pineal gland's own melatonin production through gene expression modulation. The theoretical advantage is that Pinealon restores natural, physiological melatonin secretion patterns rather than overriding them with exogenous hormone. The disadvantage is that the evidence base for Pinealon is dramatically thinner than for melatonin, which has extensive clinical trial data. They are not interchangeable — melatonin is a proven sleep aid, while Pinealon remains an experimental research compound.

Question 3

Is the Russian peptide bioregulator research credible?

Accepted Answer

This is a nuanced question. Professor Khavinson and his institute have published hundreds of papers, and the research has been influential enough to result in approved medications in Russia (e.g., Thymalin, Epithalamin). Several papers have appeared in indexed, peer-reviewed journals. However, the research has significant limitations by Western standards: most studies are small, many lack rigorous controls, independent replication by non-Russian labs is limited, and the proposed mechanism (tripeptides binding specific DNA sequences) challenges established molecular biology. The science should be evaluated with interest but also healthy skepticism. The compounds may work through mechanisms other than those proposed.

Question 4

Can tripeptides like Pinealon survive digestion and be orally bioavailable?

Accepted Answer

This is a valid concern. Larger peptides are typically degraded by gastrointestinal enzymes and have poor oral bioavailability. However, tripeptides (3 amino acids) and dipeptides have demonstrated significantly better intestinal absorption than larger peptides. The intestinal epithelium has specific peptide transporters (PepT1/SLC15A1) that actively transport di- and tripeptides across the gut wall. Studies have shown that certain tripeptides can reach systemic circulation intact after oral administration. Sublingual administration may further improve bioavailability by avoiding first-pass metabolism. Whether Pinealon specifically achieves therapeutically relevant concentrations after oral dosing has not been definitively established.

Question 5

What is the recommended cycling protocol for Pinealon?

Accepted Answer

The traditional Khavinson bioregulator protocol involves taking Pinealon daily for 10–30 days, then discontinuing for 3–6 months before the next cycle. Typically 2–4 cycles per year are recommended. The rationale is that bioregulators are thought to trigger lasting gene expression changes that persist well beyond the administration period — essentially "resetting" the target tissue's function. Continuous daily use is generally not recommended in the Khavinson model. Some practitioners combine Pinealon cycles with Epithalon cycles, targeting both pineal function and telomere maintenance. There is no clinical trial data validating any specific cycling protocol.

Route	Dosage Range	Frequency	Notes
Oral / sublingual	10–20 mg	Once daily, typically before bed	Standard Khavinson bioregulator protocol. Sublingual administration may improve bioavailability for this tripeptide. Taken 20–30 minutes before sleep.
Intranasal spray	100–300 mcg	Once daily before bed	Some suppliers offer intranasal formulations. May provide faster onset and more direct CNS access. Dosing not standardized.
Oral / sublingual (cycling protocol)	10–20 mg	Daily for 10–30 day cycles, 2–4 cycles per year	Traditional Khavinson cycling approach. Bioregulators are typically used in defined courses rather than continuously, with effects said to persist for months after each cycle.

Pinealon

Key Facts

Benefits

Dosage Protocols

Side Effects

Explore next

Frequently Asked Questions

References